48th week of 2021 patent applcation highlights part 28 |
Patent application number | Title | Published |
20210371368 | PROCESS OF MAKING CALCIUM ALPHA-KETOGLUTARATE - Methods and processes for preparing calcium salts of alpha-ketoglutarate are described herein. | 2021-12-02 |
20210371369 | NEW METHODS FOR DISPROPORTIONATION QUENCHING OF OZONIDES - The present disclosure provides improved methods of performing ozonolysis on alkenes comprising non-reductive quenching of ozonide intermediates using Bronsted bases to yield aldehyde, ketone and/or carboxylic acid products. | 2021-12-02 |
20210371370 | NITRO COMPOUND HYDROGENATION REACTION PROCESS AND HYDROGENATION REACTION APPARATUS - The present invention relates to a nitro compound hydrogenation reaction process and hydrogenation reaction apparatus, which can achieve the objects of the continuous reaction of the nitro compound and the long-period run of regeneration and activation. The nitro compound hydrogenation reaction process comprises a hydrogenation step, a regeneration step, an optional activation step and a recycling step. There exists at least one step of degassing the spent catalyst between the hydrogenation step and the regeneration step. According to circumstances, there exists at least one step of degassing the regenerated catalyst between the regeneration step and the activation step. | 2021-12-02 |
20210371371 | DOUBLE-TRAPEZOID STRUCTURAL MEMBER, FLUIDIZED APPARATUS AND NITRO COMPOUND HYDROGENATION REACTION PROCESS - A fluidized apparatus contains a double-trapezoid structural member. These fluidized apparatuses are used in the nitro compound hydrogenation reaction process. The fluidized apparatus includes a shell, a gas distributor, and an inner chamber defined by an inner wall of said shell and an upper surface of said gas distributor, in the middle region of said inner chamber is disposed a perforated plate, the perforated plate comprise an outer edge region and a center region, assuming the opening rate of the outer edge region is A1 (the unit is %), assuming the opening rate of the center region is A2 (the unit is %), then A1/A2=0-0.95. | 2021-12-02 |
20210371372 | METHOD FOR THE PRODUCTION OF ETHYLENEAMINES - The present invention relates to a process for purifying ethylenediamine, in which a) a mixture comprising water (H2O), ethylenediamine (EDA) and N-methylethylenediamine (NMEDA) is introduced into a rectification column (NMEDA removal column), where the mixture introduced comprises at least the amount of water as required for the formation of a high-boiling azeotrope of EDA and water at the appropriate bottom temperature; and the EDA-comprising bottom product from the NMEDA removal column is introduced into a second rectification column (EDA dewatering column), wherein the pressure at the top of the EDA dewatering column is adjusted such that the boiling temperature of the mixture obtained at the top is 10° C. or higher than the bottom temperature of the NMEDA removal column, which comprises (i) partly or fully condensing the vapors from the top of the EDA dewatering column in a condenser which is cooled with a medium which is at least partly evaporated during the condensation and the vapor thus formed is used at least partly to heat the evaporator of the NMEDA removal column; and/or (ii) introducing the vapors from the top of the EDA dewatering column into the NMEDA removal column. | 2021-12-02 |
20210371373 | PREPARATION METHOD FOR ESTERQUATS BASED ON OIL - The present invention relates to a process for producing an esterquat by a transesterification reaction of a fatty acid oil or a mixture comprising one or more fatty acid oils and one or more fatty acids with a tertiary hydroxy amine and then a quaternization reaction. Esterquats obtained by the method of the invention show beneficial properties in particular when used as active component in fabric softener materials. | 2021-12-02 |
20210371374 | METAL DI-AMINO ACID CHELATES OR METAL TRI-AMINO ACID CHELATES - The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates. | 2021-12-02 |
20210371375 | hTERT MODULATORS AND METHODS OF USE - The present invention provides hTERT modulators and methods for producing and using the same. In particular, the present invention provide a compound of the formula: | 2021-12-02 |
20210371376 | SALT, ACID GENERATOR, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN - A salt represented by formula (I): | 2021-12-02 |
20210371377 | CARBOXYLATE, QUENCHER, RESIST COMPOSITION AND METHOD FOR PRODUCING RESIST PATTERN - A carboxylate represented by formula (I), a quencher and a resist composition including the same: | 2021-12-02 |
20210371378 | PHENYLPYRROLIDINONE FORMYL PEPTIDE 2 RECEPTOR AGONISTS - The disclosure relates to compounds of Formulae (I)-(IX), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. | 2021-12-02 |
20210371379 | NOVEL SALT OF 4-({(4S)-1-(4-CARBAMIMIDOYLBENZOYL)-4-[4(METHYLSULFONYL)PIPERAZIN-1-YL]-L- -PROLYL}AMINO) BENZOIC ACID AND NOVEL CRYSTAL FORM THEREOF - 4-({(4S)-1-(4-Carbamimidoylbenzoyl)-4-[4-(methylsulfonyl)piperazin-1-yl]-L-prolyl}amino) benzoic acid di(4-toluenesulfonate) or dibenzenesulfonate or their crystal forms can be useful pharmaceutical ingredients because of their low hygroscopicity and excellent storage stability. | 2021-12-02 |
20210371380 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME - The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. | 2021-12-02 |
20210371381 | AN IMPROVED PROCESS FOR THE PREPARATION OF DEXMETHYL PHENIDATE HYDROCHLORIDE - Disclosed herein a process for the preparation of highly pure dexmethylphenidate hydrochloride (Formula-I) which comprises the steps of neutralization of dl-threomethylphenidate hydrochloride to dl-threo methylphenidate; subsequent resolution of dl-threo methylphenidate using amino acid or its derivatives as chiral resolution agent to yield dexmethylphenidate salt; hydrolysis of the salt and further conversion of dexmethylphenidate into its hydrochloride salt. | 2021-12-02 |
20210371382 | HYDROGENATION OF IMINES WITH RU COMPLEXES - Described herein are catalytic hydrogenation and the use of ruthenium complexes having a bidentate diphosphine ligand or two monodentate phosphine ligands, two carboxylate ligands, and optionally a diamine ligand in hydrogenation processes for the reduction of imines into the corresponding amines. | 2021-12-02 |
20210371383 | PYRIDIN-2-YL ALKYLAMINO SUBSTITUTED HYDROXAMIC ACID AND USES THEREOF - Compounds of formula I are provided: | 2021-12-02 |
20210371384 | INHIBITORS OF THE WNT/BETA-CATENIN PATHWAY - The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers. | 2021-12-02 |
20210371385 | POLYMORPHIC AND AMORPHOUS FORMS OF ISOQUINOLINONE AND METHODS OF USE THEREOF - Polymorphic and amorphous forms of 2-ethylamino-8-fluoro-3 -methyl-1-oxo-1,2-dihydro-isoquinoline-4-carboxylic acid ((S)-cyclopropyl-phenyl-methyl)-amide (also referred to herein as SJB-01). The polymorphic forms may be an alpha, a beta, or a gamma form. | 2021-12-02 |
20210371386 | MANUFACTURE OF HYDRAZINYL COMPOUNDS USEFUL IN THE MANUFACTURE OF PYRAZOLE CARBOXYLIC ACID AND DERIVATIVES, HYDRAZINYL COMPOUNDS AND THEIR USE - The present invention concerns the manufacture of hydrazinyl compounds useful in the manufacture of pyrazole carboxylic acid and derivatives thereof and processes for the manufacture of agrochemical or pharmaceutical compounds. The invention also concerns hydrazinyl compounds and their use. | 2021-12-02 |
20210371387 | GAS TREATING SOLUTIONS CONTAINING IMIDAZOLE-AMINE COMPOUNDS AND METHODS OF MAKING THE SAME - Systems comprising a composition where an imidazole is tethered to an amine and a solvent are described herein. Methods of their preparation and use are also described herein. The methods of using the systems include the reduction of volatile compounds from gas streams and a liquid stream. | 2021-12-02 |
20210371388 | Bicyclic Carboxamide with Exocyclic Urea Derivatives as Antivirals for the Treatment of HBV Infection - Pharmaceutical compositions of the invention comprise functionalized bicyclic carboxamide useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection. | 2021-12-02 |
20210371389 | ONE-STEP SYNTHESIS OF SOYBEAN POLYOLS - A method of producing a triazoline-containing compound, the method comprising reacting an alkene, which comprises at least one a C═C double bond, with an azido compound, which comprises an azide anion having the chemical formula N | 2021-12-02 |
20210371390 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME - Provided herein is the design and synthesis of novel molecular rotor fluorophores useful for detection of amyloid or amyloid like proteins. The fluorophores are designed to exhibit enhanced fluorescence emission upon associating with amyloid or amyloid like proteins as compared to unbound compound. Also disclosed herein are methods for treating diseases associated with amyloid or amyloid like proteins. | 2021-12-02 |
20210371391 | METHOD FOR PRODUCING ORGANIC COMPOUND - An object of the present disclosure is to provide a method for producing an organic compound, and a composition. The object is achieved by a method for producing a compound represented by formula (1): | 2021-12-02 |
20210371392 | FLUOROLACTONE AND METHOD FOR PRODUCING SAME - The present disclosure provides, for example, a method that can produce a fluorolactone compound from hexafluoropropylene oxide or the like in a single step. The present disclosure relates to a method for producing a compound represented by formula (1): | 2021-12-02 |
20210371393 | BENZOPYRAZOLE COMPOUND USED AS RHO KINASE INHIBITOR - The invention relates to a benzopyrazole compound used as RHO kinase inhibitor, a pharmaceutical composition and uses thereof for preparing an RHO kinase inhibiting drug, and more specifically to said compound of formula (I-1), a pharmaceutically acceptable salt and isomer thereof. | 2021-12-02 |
20210371394 | CRYSTALLINE FORM OF LNP023 - Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation. | 2021-12-02 |
20210371395 | URACIL COMPOUND AS C-MET/AXL INHIBITOR - Provided are a uracil compound represented by Formula (IV) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition of the same. Also provided is a use thereof as a c-MET/AXL inhibitor in preparing a c-MET/AXL-inhibiting drug or a drug for treating a tumor. | 2021-12-02 |
20210371396 | 1,4-DIAZOCANE COMPOUND OR SALT THEREOF - A method may produce an isoquinoline-6-sulfonamide derivative useful as a medicinal drug; and an intermediate which is used for the method, and more specifically, a 1,4-diazocane compound of formula (8), wherein R | 2021-12-02 |
20210371397 | SYNTHESIS OF OMECAMTIV MECARBIL - Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. | 2021-12-02 |
20210371398 | HETEROARYL COMPOUNDS AND THEIR USE AS MER INHIBITORS - Compounds of formula (I) [Formula should be inserted here] and a pharmaceutically acceptable salt thereof, wherein A, R | 2021-12-02 |
20210371399 | TrkA Inhibitor - The present invention relates to compound of the following structure | 2021-12-02 |
20210371400 | SMAC MIMETICS USED AS IAP INHIBITORS AND USE THEREOF - Disclosed are a class of SMAC mimetics used as IAP inhibitors, and in particular disclosed are compounds as shown in formula (I), isomers thereof, and pharmaceutically acceptable salts thereof. The IAP inhibitors are drugs for treating cancers, in particular breast cancer. | 2021-12-02 |
20210371401 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE - The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts. | 2021-12-02 |
20210371402 | 4-SUBSTITUTED PHENYL-1,3,5-TRIAZINE DERIVATIVES AS MODULATORS OF TRK RECEPTORS - There is provided a compound of formula (I), wherein R | 2021-12-02 |
20210371403 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS - Disclosed are compounds, compositions, and methods useful for treating or preventing a disease or disorder associated with a mutation in a protein. | 2021-12-02 |
20210371404 | CRYSTAL FORM OF 6-(CYCLOPROPANECARBOXAMIDO)-4-((2-METHOXY-3-(1-METHYL-1H-1,2,4-TRIAZOL-3-- YL)PHENYL)AMINO)-N-(METHYL-D3) PYRIDAZINE-3-CARBOXAMIDE - Disclosed is crystalline Form A of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d | 2021-12-02 |
20210371405 | METHOD FOR ISOLATION OF AN AROMATIC DIANHYDRIDE AND AROMATIC DIANHYDRIDES PREPARED BY THE METHOD - A method for producing an aromatic dianhydride includes reacting an aromatic diimide with a substituted or unsubstituted phthalic anhydride in an aqueous medium in the presence of an amine exchange catalyst to provide an aqueous reaction mixture including an N-substituted phthalimide, an aromatic tetraacid salt, and at least one of an aromatic triacid salt and an aromatic imide diacid salt. The method further includes removing the phthalimide from the aqueous reaction mixture by extracting the aqueous reaction mixture with an organic solvent using a sieve tray extraction column. The aromatic tetraacid salt is converted to the corresponding aromatic dianhydride. Aromatic dianhydrides prepared according to the method are also described. | 2021-12-02 |
20210371406 | Photoresponsive Nutlin Derivatives and Uses Thereof - The invention relates to the field of medicine and medicinal chemistry, more in particular to the design, manufacture and use of anti-cancer drugs that can be activated by an external stimulus that can be applied in a spatiotemporal fashion. Provided herein is a compound having the chemical structure | 2021-12-02 |
20210371407 | STEREOSELECTIVE SYNTHESIS OF INTERMEDIATE FOR PREPARATION OF HETEROCYCLIC COMPOUND - Provided is a stereoselective synthesis of an intermediate for the preparation of the heterocyclic derivative as a Cap-dependent endonuclease inhibitor. The synthesis process has the advantages of simple operation, higher yield and relatively controllable steroselectivity, such that it is suitable for large-scale production. | 2021-12-02 |
20210371408 | MICROBIOCIDAL QUINOLINE DIHYDRO-(THIAZINE)OXAZINE DERIVATIVES - Compounds of formula (I), wherein the substituents are as defined in claim 1. Futhermore, the present invention relates to agrochemical compositions which comprise compounds or compositions in agriculture or horticulture for combating, preventing or controlling infestation of plants, harvested food crops, seeds or non-living materials by phytopathogenic microorganisms, in particular fungi. | 2021-12-02 |
20210371409 | NOVEL GLP-1 RECEPTOR MODULATORS - Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as products containing such compounds, and methods of their use and synthesis. Such compounds have the structure of Formula (I) below: (I) or pharmaceutically acceptable salts thereof, wherein A, J, W | 2021-12-02 |
20210371410 | PROCESS FOR PREPARING ALECTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF - The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride. | 2021-12-02 |
20210371411 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR - Provided are a class of KRAS G12C mutein inhibitors, which relate in particular to a compound represented by formula (I), an isomer thereof, and a pharmaceutically acceptable salt thereof. | 2021-12-02 |
20210371412 | AZABENZIMIDAZOLE COMPOUNDS AND PHARMACEUTICAL - The purpose of the present invention is to provide compounds having an M3 PAM action. Examples of the present invention include azabenzimidazole compounds represented, for example, by formula [I], and pharmacologically acceptable salts thereof. These compounds have M3 PAM activity. In addition, because these compounds have M3 PAM activity, these compounds are useful as agents for the prevention or treatment of voiding and/or storage disorders in underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, and neurogenic bladder. | 2021-12-02 |
20210371413 | POLYCYCLIC AMIDES AS CYTOTOXIC AGENTS - The invention relates to a compound of formula (I): or pharmaceutically acceptable salts, solvates, tautomers, stereoisomers or mixtures thereof; wherein the fused ring moiety is a non-alkylating moiety; and wherein the compounds are useful as medicaments, in particular for use as a drug in an antibody-drug conjugate and in the treatment of a proliferative disease, a bacterial infection, a malarial infection and inflammation. | 2021-12-02 |
20210371414 | TLR8 AGONIST - A TLR8 (Toll-like receptor 8) agonist, a compound of the structure shown in formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof. | 2021-12-02 |
20210371415 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY - Provided are a JAK kinase inhibitor, preparation and use thereof. In particular, provided is a compound of Formula I, wherein each group is as described in the specification. The compound has an excellent JAK inhibitory activity, and therefore can be used to prepare pharmaceutical compositions for the treatment of cancer and other diseases related to JAK activity. | 2021-12-02 |
20210371416 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5- DISUBSTITUTED -3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES - The present invention provides compounds useful as c-Met protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of c-Met kinase mediated disease or disorders with them. | 2021-12-02 |
20210371417 | AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS - The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. | 2021-12-02 |
20210371418 | PROTEIN KINASE INHIBITORS, PREPARATION METHOD AND MEDICAL USE THEREOF - The embodiments disclosed herein provide compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, or a pharmaceutically acceptable salt or solvate of the compounds as shown in formula I or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer, a deuterated compound, a prodrug or a mixture thereof, wherein R | 2021-12-02 |
20210371419 | PROCESSES FOR PREPARING A DIAZABICYCLOOCTANE COMPOUND - A process for preparing a diazabicyclooctane compound represented by the following formula (I): | 2021-12-02 |
20210371420 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF - The present invention generally relates to compounds as a dual kinase-demethylase inhibitor useful for the treatment of diseases mediated by a kinase and/or a histone demethylase, such as inflammation, cancer, viral and bacterial infections, neurological and immunological disorders. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention. | 2021-12-02 |
20210371421 | NOVEL COMPOUNDS AND METHODS - The present invention relates to use of particular substituted heterocycle fused gamma-carbolines as described herein, in free, pharmaceutically acceptable salt or prodrug form, and pharmaceutical composition comprising the same optionally in combination with one or more agents, for the prophylaxis or treatment of one or more disorders associated with dementia, particularly behavioral or mood disturbances (e.g., agitation/aggression), psychosis, depression and sleep disturbances among others in patients suffering from dementia. | 2021-12-02 |
20210371422 | MORPHINAN DERIVATIVE - A compound represented by the following general formula (I), | 2021-12-02 |
20210371423 | Ibogaine-related compounds and corresponding methods - The present invention relates to Ibogaine derivatives and related methods. It more specifically relates to deutero- and fluoro-derivatives of Ibogaine and related methods. In one aspect, the present invention provides a compound. The structure of the compound is shown as compound | 2021-12-02 |
20210371424 | OXIME GROUP-CONTAINING CONDENSED HETEROCYCLIC COMPOUND OR SALT THEREOF, AGRICULTURAL AND HORTICULTURAL INSECTICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE INSECTICIDE - Provided are an oxime group-containing condensed heterocyclic compound or a salt thereof, preferably a condensed heterocyclic compound represented by general formula (1): | 2021-12-02 |
20210371425 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF - Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer. | 2021-12-02 |
20210371426 | CHLOROTONIL DERIVATIVES - The present invention relates to novel chlorotonil derivatives of formula (I) and the use thereof for the treatment or prophylaxis of bacterial infections and malaria. | 2021-12-02 |
20210371427 | Organic Compound, Light-Emitting Device Material, Light-Emitting Device, Light-Emitting Apparatus, Light-Emitting Module, Electronic Device, and Lighting Device - An organic compound with high heat resistance is provided. A novel organic compound that can be used for a light-emitting device that emits red light or near-infrared light is provided. An organic compound represented by General Formula (G0) is provided. In General Formula (G0), Q represents oxygen or sulfur, Ar1 represents a substituted or unsubstituted fused aromatic ring, R1 and R2 each independently represent hydrogen or a group with 1 to 100, inclusive, carbon atoms in total, and at least one of R1 and R2 has a hole-transport skeleton or a fused ring. | 2021-12-02 |
20210371428 | FUSED THIOPHENE MOLECULE AND p-TYPE SEMICONDUCTOR FILM AND ELECTRONIC DEVICE - To provide a fused thiophene molecule having further sufficiently high hole mobility. Disclosed is a fused thiophene molecule that has seven aromatic rings containing three thiophene rings in one molecule and in which the seven aromatic rings have one or two naphthalene structures. And, semiconductor devices including a layer using the fused thiophene molecule are disclosed. | 2021-12-02 |
20210371429 | N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 - The present invention relates to compounds of formula I: | 2021-12-02 |
20210371430 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF - The present invention relates to a heterocyclic amide inhibiting RIP1 kinase and the use thereof, and specifically, to a compound of formula I, its pharmaceutically acceptable salts, stereoisomers, enantiomers, diastereomers, atropisomers, optical isomers, racemates, polymorphs, solvates or isotopically labeled compounds, a pharmaceutical composition comprising the compound, and the pharmaceutical use thereof. The compound is particularly effective for treatment of diseases or disorders mediated by RIP1 kinase. | 2021-12-02 |
20210371431 | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS - The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like. | 2021-12-02 |
20210371432 | Tetrahydro-1H-pyrazino[2,1-a]isoindolylquinoline Compounds for the Treatment of Autoimmune Disease - The present invention relates to compounds of formula (I), wherein R | 2021-12-02 |
20210371433 | Novel Monocyclic And Bicyclic Ring System Substituted Carbanucleoside Analogues For Use As PRMT5 Inhibitors - The present invention relates to novel novel monocyclic and bicyclic ring system substituted carbanucleoside analogues of Formula (I), wherein the variables have the meaning defined in the claims. The compounds according to the present invention are useful as PRMT5 inhibitors. The invention further relates to pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament. | 2021-12-02 |
20210371434 | BASIC COPPER GLUCONATE - Basic copper gluconate having a formula of C | 2021-12-02 |
20210371435 | STABLE ALKALI AMIDE SOLUTIONS AND PROCESSES FOR PREPARING SAME - The object of the invention are solutions of alkali metal amides MNR | 2021-12-02 |
20210371436 | NOVEL HEAVY METAL ION-LIGAND-COMPLEXES USEFUL AS EX VIVO CONTRAST AGENT FOR A COMPUTED TOMOGRAPHY SCANNING OF A BIOLOGICAL SAMPLE, EX VIVO METHOD FOR INVESTIGATING A BIOLOGICAL SAMPLE, AND USE OF THE COMPLEXES - The present invention relates to specific complexes comprising heavy metal ions having an atomic number of 29 or higher and 83 or lower (preferably 29 or higher and 81 or lower) and one or more ligand(s) selected from the group consisting of specific xanthene derivatives, preferably eosin Y and/or erythrosin B ligand(s). In particular, the invention relates to the use of the complexes as ex vivo contrast agents for a computed tomography scanning of a biological sample. Moreover, the invention relates to specific ex vivo methods for investigating a biological sample by means of computed tomography scanning methods, wherein the method comprises staining the biological sample with a solution comprising one or more of the complex(es); or wherein the method comprises staining the biological sample with a staining solution comprising one or more specific xanthenes derivatives (e.g. eosin Y and/or erythrosin B), and separately contacting the biological sample with one or more staining solution(s) comprising one or more heavy metal ions having an atomic number of 29 or higher and 83 or lower (preferably 29 or higher and 81 or lower). | 2021-12-02 |
20210371437 | COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED FROM A DIASTEREOISOMERICALLY ENRICHED PCTA AND PREPARATION AND PURIFICATION PROCESS - The present invention relates to a complex of formula (II) constituted of at least 90% of a diastereoisomeric excess comprising a mixture of isomers II-RRR and II-SSS of formulae: | 2021-12-02 |
20210371438 | ADDUCTS OF TRIPHENYLPHOSPHINE AND TRIPHENYLPHOSPHITE AND THEIR USE FOR THE BROMINATION OF PRIMARY ALCOHOLS - The present invention relates to the use of novel adducts of general formula (I) TPP | 2021-12-02 |
20210371439 | Antiviral Compounds - The present application provides compounds and methods of treating viral infections, including viral infections caused by HIV or HTLV. | 2021-12-02 |
20210371440 | TLR7 AND / OR TLR8 AGONISTS - The invention relates to a novel lipidated oxoadenine compound of formula (I) and its use as a vaccine adjuvant and as a TLR7 and/or TLR8 agonist. | 2021-12-02 |
20210371441 | PLATINUM COMPLEX, ITS PREPARATION AND THERAPEUTIC USE - A platinum complex comprises a chemical structure of Structure I: | 2021-12-02 |
20210371442 | ORGANOMETALLIC COMPOUNDS - The present patent application relates to novel allyl cobalt complexes, to a process for their preparation and to their use for vapor deposition. | 2021-12-02 |
20210371443 | METHOD FOR PRODUCING OXIDIZED LIGNINS - The invention is directed to a method for producing oxidized lignins. | 2021-12-02 |
20210371444 | METHOD FOR PRODUCING OXIDIZED LIGNINS - The present invention is directed to a method for producing oxidized lignins. | 2021-12-02 |
20210371445 | STEVIOL GLYCOSIDE COMPOSITION - The present invention relates to a composition comprising one or more steviol glycosides which composition comprises kaurenoic acid in an amount of no more than 150 ppm. The invention also relates to a method for preparing a steviol glycoside composition, which method comprises: providing a steviol glycoside composition; combining the steviol glycoside composition with a solvent to form a steviol glycoside solution; and crystallizing a steviol glycoside composition from the steviol glycoside solution, wherein the crystallization is carried out at pH7.0 or below. The invention also relates to a method for reducing the kaurenoic acid content of a steviol glycoside composition, which method comprises: providing a steviol glycoside composition which comprises kaurenoic acid; combining the steviol glycoside composition with a solvent to form a steviol glycoside solution; and crystallizing a steviol glycoside composition from the steviol glycoside solution, wherein the crystallization is carried out at pH7.0, thereby to reduce the amount of kaurenoic acid in the steviol glycoside composition. | 2021-12-02 |
20210371446 | SIRT1 ACTIVATING COMPOUNDS - Provided herein are methods and compositions for preventing or treating aging, or an aging-related disorder, a disorder associated with inflammation, or for modulating an immune response in a subject in need thereof. In some embodiments, the methods comprise administering to the subject an effective amount of a compound of Formulas I-XIII. | 2021-12-02 |
20210371447 | NUCLEOSIDE DERIVATIVE AND USE THEREOF - A nucleoside derivative represented below, or a salt thereof. | 2021-12-02 |
20210371448 | METHOD FOR PREPARING CANGRELOR TETRASODIUM SALT - The present application relates to a method for prepare a Cangrelor tetrasodium salt, comprising: using N-[2-(methylthio)ethyl]-2-[(3,3,3-trifluoropropyl)sulfonyl]adenosine as a raw material to undergo two steps of reaction to obtain a reaction solution containing the Cangrelor tetrasodium salt; separating and purifying once by C18 silica gel column chromatography so as to obtain a Cangrelor tetrasodium salt pure product. The present application has the advantages of short synthesis route, mild reaction conditions, sufficient reaction, simple operation, high product yield, high purity, and environmental friendliness, and is suitable for large-scale preparation. | 2021-12-02 |
20210371449 | MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF - Compounds that modulate the conversion of AMP to adenosine by 5′-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided. | 2021-12-02 |
20210371450 | PRODUCTION METHOD FOR OLIGONUCLEOTIDES - A method for producing an oligonucleotide, including a step of removing a temporary protecting group of a 5′-hydroxyl group by adding an acid to a protected oligonucleotide having a phosphorothioate (PS), phosphate (PO) or H-phosphonate moiety, and deacylating a by-product having an acylated 5′-hydroxyl group by solvolysis can complete a condensation reaction to improve a condensation yield, and can markedly reduce impurities such as single base deletion form (N-1mer) and the like. | 2021-12-02 |
20210371451 | CYCLIC-DI-AMP SODIUM SALT CRYSTAL - A lyophilized product of cyclic-di-AMP requires special production equipment and is thus not suitable for large-scale production. Crystals of cyclic-di-AMP free acid are unstable under severe conditions at 105° C. Then, the present invention addresses the problem of providing a cyclic-di-AMP crystal that can be easily acquired in a large amount and is very stable under the severe conditions at 105° C. Crystals of c-di-AMP sodium salt according to the present invention are extremely stable even under the severe conditions at 105° C. Further, the crystals of c-di-AMP sodium salt according to the present invention can be prepared in a large amount by a simple process including adjusting a c-di-AMP aqueous solution at pH 5.2-12.0 and then adding an organic solvent thereto. | 2021-12-02 |
20210371452 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS - Provided herein are methods and compositions for synthesizing 5′Capped RNAs wherein the initiating capped oligonucleotide primers have the general form | 2021-12-02 |
20210371453 | GLYCOCONJUGATION PROCESS - The present disclosure relates generally to methods of preparing glycoconjugates containing a saccharide conjugated to a carrier protein by use of stable nitroxyl radical related agent/oxidant as an oxidizing agent, to immunogenic compositions comprising such glycoconjugates, and to methods for the use of such glycoconjugates and immunogenic compositions. | 2021-12-02 |
20210371454 | Solutions of Quaternary and Tertiary Ammonium Cation Detergents to Denature Proteins, and Kits for Making Them - Ammonium cation detergents comprising a quaternary or tertiary ammonium cation can be used as detergents to denature proteins and are particularly useful in denaturing glycoproteins or glycopeptides prior to enzymatic deglycosylation. Ammonium cation detergents with sulfate or sulfonate anions are particularly useful. | 2021-12-02 |
20210371455 | METHODS AND COMPOSITIONS COMPRISING REDUCED LEVEL OF HOST CELL PROTEINS - The present disclosure pertains to compositions with reduced presence of host-cell proteins and methods of making such compositions. In particular, it pertains to compositions methods of making compositions with reduced presence of host-cell proteins from a host-cell. | 2021-12-02 |
20210371456 | PROCESSING PROTEIN - A method comprising feeding MF feedstock to a cross-flow microfilter. The MF feedstock includes at least 5% protein solids and has a conductivity of less than 10 mS/cm. | 2021-12-02 |
20210371457 | CHROMATOGRAPHY-FREE ANTIBODY PURIFICATION METHOD - The present invention relates method for purifying antibodies, said method comprising a limited number of steps while still allowing obtaining high yields of purified antibodies with an appropriate degree of purity. Briefly, this method comprises only filtration and precipitation steps, omitting the need for chromatography steps. | 2021-12-02 |
20210371458 | TERTIARY AMINO LIPIDATED CATIONIC PEPTIDES FOR NUCLEIC ACID DELIVERY - The present disclosure relates to tertiary amino lipidated and/or PEGylated cationic peptide compounds and complexes thereof with nucleic acids for endocellular delivery, methods for preparing the compounds and complexes, and methods for delivering polyanionic compounds to cells. | 2021-12-02 |
20210371459 | DIMERIC PEPTIDE INHIBITORS OF APOPTOSIS PROTEINS - The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by IAPs. In particular the present compounds and compositions may be used to treat IAP-mediated ovarian cancer and hepatitis B infection. | 2021-12-02 |
20210371460 | TARGETED NITROXIDE AGENTS - Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage caused by radiation. The method comprises delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation. | 2021-12-02 |
20210371461 | Novel chemiluminescent substrates for Factor Xa - The present invention relates to chemiluminescent substrates for blood clotting enzyme Factor Xa. The substrates are particularly useful for assaying coagulation factors and for quantifying an anticoagulant in a sample. | 2021-12-02 |
20210371462 | CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME - The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided. | 2021-12-02 |
20210371463 | Modified Netrin-1 Peptides and Compositions for Cardioprotection - Disclosed herein are modified netrin-1 peptides and compositions thereof and methods of using thereof to confer cardioprotection. In some embodiments, the present invention provides methods of using one or more modified netrin-1 peptides and compositions thereof In some embodiments, the present invention provides a method of stimulating, increasing, or enhancing nitric oxide production by endothelial cells, which comprises administering to the endothelial cells one or more modified netrin-1 peptides or a composition thereof. | 2021-12-02 |
20210371464 | PEPTIDE HAVING CYTOPROTECTIVE EFFECT AGAINST ENVIRONMENTAL POLLUTANT AND USE THEREOF - Provided are a peptide with a cytoprotective effect against environmental pollutants and a use thereof. The peptide consisting of an amino acid sequence of SEQ ID NO: 1, 2, or 3 directly binds to 2,3,7,8-tetrachlorodibenzo-p-dioxin (hereinafter, referred to as TCDD), known as being the most toxic among the class of dioxins, to prevent dermal penetration and the activation mechanism of AhR by TCDD and polycyclic aromatic hydrocarbons contained in fine dust. Such a direct cytoprotective effect against environmental pollutants is distinguished from preexisting methods that are configured to indirectly block opportunities to contact these materials or to reduce toxicity through barrier reinforcement. | 2021-12-02 |
20210371465 | METHOD OF USING A TLR9 ANTAGONIST AS AN ANTI-INFLAMMATORY AND ANTI-FIBROTIC AGENT - Methods of treating or ameliorating inflammatory disorders and fibrosis are described. The methods include administering a therapeutically effective amount of an oligonucleotide inhibitor of TLR9 to an individual suffering from an inflammatory disorder or fibrosis. Also described are kits for treating or ameliorating inflammatory disorders and fibrosis. | 2021-12-02 |
20210371466 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS - The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo. | 2021-12-02 |
20210371467 | SPLIT INTEINS WITH EXCEPTIONAL SPLICING ACTIVITY - Embodiments of the present invention relate to inteins, split inteins, compositions comprising inteins and methods for use of these. | 2021-12-02 |